CD40 ligand-enhanced cells and methods of modulating an immune response to an antigen
AssigneeGenitrix, LLC
InventorAndrew H. Segal
Life of this patent
Estimating the term…
Abstract
The invention provides for a method of vaccinating a mammal to a selected antigen, wherein the method comprises administering to a mammal a vaccine composition comprising a CD40 ligand-enhanced cell, wherein the CD40 ligand-enhanced cell comprises a selected antigen and is admixed with an engineered ligand for CD40.
Claims68
A method of vaccinating a mammal to a selected antigen, the method comprising administering to a mammal a vaccine composition comprising a CD40 ligand-enhanced cell, wherein said CD40 ligand-enhanced cell comprises said selected antigen and is admixed with an engineered ligand for CD40.
A method of vaccinating a mammal to a selected antigen, the method comprising administering to a mammal a vaccine composition comprising a CD40 ligand-enhanced cell.
A method of vaccinating a mammal to a selected antigen, the method comprising contacting an APC in vitro with a CD40 ligand-enhanced cell comprising a selected antigen, for a time sufficient to permit internalization of said selected antigen by said APC, and administering a vaccine composition comprising said contacted APC to a mammal.
A method of vaccinating a mammal to a selected antigen, the method comprising contacting an APC in vitro with a CD40 ligand-enhanced, opsonin-enhanced cell comprising a selected antigen, for a time sufficient to permit internalization of said selected antigen by said APC, and administering a vaccine composition comprising said contacted APC to a mammal.
A method of vaccinating a mammal to a selected antigen, the method comprising administering to a mammal a vaccine composition comprising an opsonin-enhanced pathogenic cell and a CD40 ligand-enhanced pathogenic cell, wherein said opsonin of said opsonin-enhanced cell selected from the group consisting of mannose binding protein or the alpha′ chain of C3b.
A composition comprising a CD40 ligand-enhanced pathogenic cell.
A composition comprising a CD40 ligand-enhanced cell and a cytokine.
A composition comprising a host cell comprising a CD40 ligand-enhanced'cell into which a recombinant nucleic acid encoding an antigen has been artificially introduced and;
- wherein said host cell expresses said antigen.
A composition comprising a CD40 ligand-enhanced cell, wherein said cell is substantially unable to divide in vitro.
A composition comprising CD40 ligand-enhanced cells and a pharmaceutically acceptable carrier.
An engineered ligand for CD40.
Dependencies are inferred from the claim text.